Cancer Stem Cells: An Innovative Therapeutic Approach

作者: Roberto Scatena , Patrizia Bottoni , Alessandro Pontoglio , Salvatore Scarà , Bruno Giardina

DOI: 10.1007/978-1-4614-0809-3_15

关键词:

摘要: Cancer stem cells (CSCs) are gaining prominence in oncology. The characterization of the molecular phenotype CSCs or “cancer cell-like cells” can clarify several intriguing and obscure aspects cancer pathophysiology (e.g., cell dormancy, chemoresistance, metastasis) could represent a fundamental advance terms early diagnosis selective therapy for cancer. Moreover, understanding underlying pathogenetic mechanisms expand therapeutic applications normal adult by reducing risk disordered uncontrolled potentially tumorigenic differentiation. An explosion emerging diagnostic options treatment that selectively target has occurred recent years. These include targeting surface proteins, various activated signaling pathways, different molecules niche, drug resistance mechanisms. Importantly, approaching research investigating pathogenesis these is increasing knowledge disease, emphasizing certain concepts have been partially neglected facilitating global vision complex biology.

参考文章(115)
Peter W. Atadja, HDAC Inhibitors and Cancer Therapy Epigenetics and Disease. ,vol. 67, pp. 175- 195 ,(2011) , 10.1007/978-3-7643-8989-5_9
A. Blair, D.E. Hogge, L.E. Ailles, P.M. Lansdorp, H.J. Sutherland, Lack of Expression of Thy-1 (CD90) on Acute Myeloid Leukemia Cells With Long-Term Proliferative Ability In Vitro and In Vivo Blood. ,vol. 89, pp. 3104- 3112 ,(1997) , 10.1182/BLOOD.V89.9.3104
Monica Fornier, Conleth G. Murphy, HER2-positive breast cancer: beyond trastuzumab. Oncology. ,vol. 24, pp. 410- 415 ,(2010)
Patrick A Baeuerle, Ralf Bargou, Peter Kufer, BiTE: Teaching antibodies to engage T-cells for cancer therapy. Current Opinion in Molecular Therapeutics. ,vol. 11, pp. 22- 30 ,(2009)
Ute Koch, Freddy Radtke, Notch Signaling in Solid Tumors Current Topics in Developmental Biology. ,vol. 92, pp. 411- 455 ,(2010) , 10.1016/S0070-2153(10)92013-9
Peter F Bross, Julie Beitz, Gang Chen, Xiao Hong Chen, Eric Duffy, Lydia Kieffer, Sandip Roy, Rajeshwari Sridhara, Atiqur Rahman, Grant Williams, Richard Pazdur, None, Approval Summary: Gemtuzumab Ozogamicin in Relapsed Acute Myeloid Leukemia Clinical Cancer Research. ,vol. 7, pp. 1490- 1496 ,(2001)
Sheila A Doggrell, The hedgehog pathway inhibitor GDC-0449 shows potential in skin and other cancers. Expert Opinion on Investigational Drugs. ,vol. 19, pp. 451- 454 ,(2010) , 10.1517/13543780903571649
L. Deng, S. Hu, A. R. Baydoun, J. Chen, X. Chen, X. Cong, Aspirin induces apoptosis in mesenchymal stem cells requiring Wnt/beta-catenin pathway. Cell Proliferation. ,vol. 42, pp. 721- 730 ,(2009) , 10.1111/J.1365-2184.2009.00639.X
R. L. Yauch, G. J. P. Dijkgraaf, B. Alicke, T. Januario, C. P. Ahn, T. Holcomb, K. Pujara, J. Stinson, C. A. Callahan, T. Tang, J. F. Bazan, Z. Kan, S. Seshagiri, C. L. Hann, S. E. Gould, J. A. Low, C. M. Rudin, F. J. de Sauvage, Smoothened mutation confers resistance to a Hedgehog pathway inhibitor in medulloblastoma Science. ,vol. 326, pp. 572- 574 ,(2009) , 10.1126/SCIENCE.1179386
Glen J. Weiss, Mitesh J. Borad, Christine L. Hann, Julie R. Brahmer, Howard M. Mackey, Bertram L. Lum, Walter C. Darbonne, James C. Marsters, Frederic J. de Sauvage, Jennifer A. Low, Daniel D. Von Hoff, Patricia M. LoRusso, Charles M. Rudin, Josina C. Reddy, Robert L. Yauch, Raoul Tibes, Inhibition of the Hedgehog Pathway in Advanced Basal-Cell Carcinoma New England Journal of Medicine. ,vol. 361, pp. 1164- 1172 ,(2009) , 10.1056/NEJMOA0905360